FREDDO
K242132 · Fabinject Lndustria E Comercio Lmportacao E Exportacao Ltda · GEX · Oct 18, 2024 · General, Plastic Surgery
Device Facts
| Record ID | K242132 |
| Device Name | FREDDO |
| Applicant | Fabinject Lndustria E Comercio Lmportacao E Exportacao Ltda |
| Product Code | GEX · General, Plastic Surgery |
| Decision Date | Oct 18, 2024 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 878.4810 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The Freddo is indicated to be used to: Minimize pain and thermal injury during laser and dermatological treatments and for temporary topical anesthetic relief for injections.
Device Story
Non-invasive cold air therapy device; cools and dehumidifies air to provide localized, contactless skin cooling. Mechanical assembly includes housing, chassis with rollers, compressor, evaporator, condenser, and fans. Operated via membrane keyboard on upper front cover; LCD display provides status. Used in clinical settings by healthcare professionals. Device produces cold air stream directed at patient skin; cooling achieved via conduction, evaporation, and forced convection. Benefits include pain reduction and thermal injury prevention during procedures. Software manages device initialization, cooling circuit hardware, and user interface.
Clinical Evidence
Bench testing only. Device performance verified against IEC 60601-1 (electrical safety), IEC 60601-1-2 (EMC), and IEC 62304 (software lifecycle). Usability testing performed per IEC 62366-1. No clinical data provided.
Technological Characteristics
Closed-loop cooling system using R404 refrigerant; compressor, evaporator, condenser, and fan assembly. Metal enclosure; IPX0 rating. Operates at 120V/60Hz. Cooling output: -17°C to -28°C (± 3°C) at 160-780 L/min. User interface: membrane keyboard and LCD display. Software developed per IEC 62304.
Indications for Use
Indicated for patients undergoing laser and dermatological treatments to minimize pain and thermal injury, and for temporary topical anesthetic relief for injections.
Regulatory Classification
Identification
(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
Predicate Devices
Related Devices
- K220020 — Cryo 7 · Zimmer Medizinsysteme GmbH · Feb 4, 2022
- K090618 — CYNOSURE SMARTCOOL FAMILY COLD AIR DEVICE: SMARTCOOL, SMARTCOOL 6 AND CRYO C · Cynosure, Inc. · Apr 14, 2009
- K233416 — Cryojet Plus (SHE-ACP001-1) · Beijing Sano Laser S&T Development Co.,Ltd · Feb 6, 2024
- K060395 — CRYO, MODEL V6.0 · Zimmer Elektromedizin GmbH · Feb 24, 2006
- K962537 — INCARE HOT/ICE LITE MACHINE · Hollister, Inc. · Nov 27, 1996
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
October 18, 2024
Fabinject Industria e Comercio Importacao e Exportacao Ltda % Aleksandro Gardano Principal Consultant, Regulatory Affairs Regulab 34 Pinar del Rio Avenue Brownsville, Texas 78526
Re: K242132
Trade/Device Name: FREDDO Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX Dated: July 2, 2024 Received: July 22, 2024
Dear Aleksandro Gardano:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/ofdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (OS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Re"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system.
Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn).
{2}------------------------------------------------
Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/deviceadvice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
TANISHA L. HITHE -S
Tanisha Hithe Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
# Indications for Use
510(k) Number (if known) K242132
Device Name Freddo
Indications for Use (Describe) The Freddo is indicated to be used to:
Minimize pain and thermal injury during laser and dermatological treatments and for temporary topical anesthetic relief for injections.
Type of Use (Select one or both, as applicable)
| <span style="font-size: 10pt;"> <span style="font-family: Symbol;">☒</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> |
|------------------------------------------------------------------------------------------------------------------------------------------|
| <span style="font-size: 10pt;"> <span style="font-family: Symbol;">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> |
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
# 510(k) SUMMARY
This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR 807.92.
| I. SUBMITTER: | Fabinject Ind Com Imp Exp Ltda<br>Rua Eng Joao Porfirio Macedo, 401<br>12072-270 Taubaté-SP, Brazil<br>Establishment Registration: 02.289.126/0001-53 |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Mr. Gianmaria Cominato Filho<br>Manager, CEO<br>Phone: +55-12-36021415<br>Cell phone: +55-11-995881511<br>E-mail: gcf@fabinject.com.br |
| CONTACT: | Aleksandro Garrido Gardano<br>Principal Consultant Regulatory Affairs<br>Phone: +55-11-36021415<br>Cell phone: +55-11-993352632<br>E-mail: agg@fabinject.com.br |
| DATE PREPARED: | October 17, 2024 |
| II. DEVICE: | |
| TRADE NAME: | Freddo |
| COMMON NAME: | Laser surgical instrument for use in general and plastic<br>surgery and in dermatology |
| CLASSIFICATION NAME: | Powered Laser Surgical |
| Instrument DEVICE CLASSIFICATION: | Class II, 21 CFR |
| §878.4810 PRODUCT CODE: | GEX |
| III. PREDICATE DEVICE: | Cryo V6.0 (K060395) |
# IV. DEVICE DESCRIPTION:
The Freddo is a non-invasive therapeutic device. The cold air therapy device cools and dehumidifies the air, which can be used to minimize pain and thermal injury during laser and dermatological treatments and for temporary topical anesthetic relief for injections. The cold air therapy device is intended to cool the patient's skin locally and is intended to be used contactless. The subject Freddo device is substantially equivalent as the currently cleared Cryo 6 (K060395).
{5}------------------------------------------------
The mechanical assembling consists of a housing, a chassis with 4 rotating rollers and a shelf plate. The chassis includes all technical components, like compressor, evaporator, condenser, fans, and all electrical power components. On the upper front cover, the user interface control it operated via membrane keyboard.
The software controls the device initialization, the hardware components for the cooling circuit as well as the user interface. The user interface can be controlled via membrane keyboard. The software controls the device initialization, the hardware components for the cooling circuit as well as the user interface.
#### V. INDICATONS FOR USE:
Freddo is indicated to be used to:
Minimize pain and thermal injury during laser and dermatological treatments and for temporary topical anesthetic relief for injections.
### VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE:
The technological characteristics and operating principle associated with the treatment of Freddo delivers remain unchanged from the predicate device produces cold air for blowing on patient's skin locally and is intended to be contactless.
The technological similarities and differences between the subject device (Freddo) and the predicate device (Zimmer Cryo-6) are described below in the comparison table. The differences do not raise any new questions regarding safety or effectiveness.
{6}------------------------------------------------
| Comparison with the<br>Predicate Device | SUBJECT DEVICE<br>Fabinject Ind Com Imp Exp Ltda<br>Freddo (This Submission) | PREDICATE DEVICE<br>Zimmer MedizinSysteme GmbH<br>Cryo V6.0 (K060395) | Discussion |
|-------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Product Code and<br>Regulation | General & Plastic Surgery 21<br>CFR 878.4810<br>GEX - Powered Laser Surgical<br>Instrument | General & Plastic Surgery 21<br>CFR 878.4810<br>GEX - Powered Laser Surgical<br>Instrument | Identical |
| Device Description | The Freddo Cold Air Device utilizes<br>a compressor, evaporator, and fan<br>to cool the patient's skin locally and<br>contactless. | The Zimmer Cryo V6.0 Cold Air<br>Device utilizes a compressor,<br>evaporator and fan to cool room air<br>and then direct it onto skin. | Identical |
| Intended Use | The Freddo is intended to minimize<br>pain and thermal injury during laser<br>and dermatological treatments and<br>for temporary topical anesthetic<br>relief for injections. | The Cryo V6.0 Cold Air Device is<br>intended to minimize pain and thermal<br>injury during laser and dermatological<br>treatments and for temporary topical<br>anesthetic relief for injections. | Identical |
| Performance<br>Characteristics<br>Measurement at<br>device outlet | -17°C to -28°C (± 3°C)<br>At an air speed of<br>160 to 780 liters/minute (± 10%). | -31°C<br>At an air speed of<br>100 to 1000 liters/minute. | Similar, not<br>significantly different |
| Cooling Method,<br>Operation principle | Cooling agent-based condenser and<br>evaporation system. Cold air is<br>produced which is then directed onto<br>the skin. Conduction,<br>evaporation, and forced<br>convection cool the skin. | Cooling agent-based condenser and<br>evaporation system. Cold air is<br>produced which is then directed onto<br>the skin. Conduction,<br>evaporation, and forced convection<br>cool the skin. | Identical |
| Cooling Material | Gas (Air) | Gas (Air) | Identical |
| Mains Voltage | 120V / 60Hz | 100V - 120V / 50-60Hz | Similar, not important<br>for the device safety<br>and effectiveness<br>evaluation |
| Main Fuse | 16A circuit breaker in main switch for<br>120V<br>10A circuit breaker in main switch for<br>220V | 16A circuit breaker in main switch | Similar, not important<br>for the device safetv<br>and effectiveness<br>evaluation |
| Power Consumption | Max. 11A | Max. 9 - 11A | No impact |
| IP classification | IPX0 | IPX0 | Identical |
| Design | Metal enclosure | Metal enclosure | Identical |
| Materials | Environmentally approved R404,<br>closed loop cooling system | Environmentally approved R507,<br>closed loop cooling system | Both environmentally<br>approved, no impact |
| Cooling spot Size | Varies with distance from distal end<br>of air hose to tissue - 10cm² @ 5cm<br>distance | Varies with distance from distal end<br>of air hose to tissue - 10cm² @ 5cm<br>distance | Identical |
| Fan speed settings | 1 - 3 | 1 - 9 | No impact |
| Comparison with the<br>Predicate Device | SUBJECT DEVICE<br>Fabinject Ind Com Imp Exp Ltda<br>Freddo (This Submission) | PREDICATE DEVICE<br>Zimmer MedizinSysteme GmbH<br>Cryo V6.0 (K060395) | Discussion |
| Interface | N/A | N/A | Identical |
| Therapy time,<br>treatment time | 15:00 – 90:00 min timer – user<br>selectable | 1-99 minute timer - user<br>selectable | Similar, not<br>significantly<br>different |
| Time delay to<br>operate | Immediate from pressing start button<br>once unit achieves standby mode | Immediate from pressing start button<br>once unit achieves standby mode | Identical |
| Compatibility with<br>the environment | R404<br>Ozone destruction level 0 | R507<br>Ozone destruction level 0 | Both<br>environmentally<br>approved, no<br>impact |
| Display | LCD display | LCD display | Identical |
| Weight without<br>accessories | 55 kg | 60 kg | No impact |
| Dimensions | H 710 mm x W 480 mm x D 510 mm | H 645 mm x W 390 mm x D 680 mm | Different dimensions<br>have no influence<br>on the device safety<br>and<br>effectiveness<br>evaluation |
| Operating Ambient<br>Temperature and<br>Humidity | Temperature: 10 - 35°C<br>Humidity: 20-80% relative humidity<br>without condensation<br>Air pressure: 900-1060 hPa | Temperature: 10 - 35°C<br>Humidity: 20-80% relative humidity<br>without condensation<br>Air pressure: 900-1060 hPa | Identical |
| Storage<br>and<br>Transport | Storage: Temperature: 0 - 40°C<br>Humidity: 10-90% relative humidity<br>without condensation<br>Air pressure: 600-1060 hPa<br>Transport: Temperature: -10 - 50°C<br>Humidity: 10-90% relative humidity<br>without condensation<br>Air pressure:600-1060 hPa | Storage: Temperature: 0 - 40°C<br>Humidity: 10-90% relative humidity<br>without condensation<br>Air pressure: 600-1060 hPa<br>Transport: Temperature: -10 - 50°C<br>Humidity: 10-90% relative humidity<br>without condensation<br>Air pressure:600-1060 hPa | Identical |
| Environmental<br>Specifications | For indoor use only | For indoor use only | Identical |
{7}------------------------------------------------
{8}------------------------------------------------
### VII. PERFORMANCE DATA:
The Freddo has been investigated and tested against and complies with the following recognized standards:
| Standards | Standards<br>Organization | Standards Title |
|-----------------------------------------------------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 60601-1 Edition 3.2 2020-08<br>CONSOLIDATED VERSION | IEC | Medical electrical equipment - Part 1: General requirements for basic<br>safety and essential performance |
| 60601-1-2 Edition 4.1 2020-<br>09 CONSOLIDATED<br>VERSION | IEC | Medical electrical equipment - Part 1-2: General requirements for<br>basic safety and essential performance - Collateral standard:<br>Electromagnetic disturbances - Requirements and tests |
| 60601-1-6 Edition 3.2 2020-<br>07 CONSOLIDATED<br>VERSION | IEC | Medical electrical equipment - Part 1-6: General requirements for<br>basic safety and essential performance - Collateral standard: Usability |
| 62366-1 Edition 1.1<br>2020-06<br>CONSOLIDATED VERSION | IEC | Medical devices - Part 1: Application of usability engineering to<br>medical devices |
| 62304 Edition 1.1<br>2015-06<br>CONSOLIDATED VERSION | IEC | Medical devices software -software life cycle processes |
| 14971 Third Edition<br>2019-12 | ISO | Medical devices - Application of risk management to medical devices |
| 15223-1 Fourth edition<br>2021-07 | ISO | Medical devices - Symbols to be used with medical device labels,<br>labeling, and information to be supplied - Part 1: General<br>requirements |
| 10993-1 Fifth edition<br>2018-08 | ISO | Biological evaluation of medical devices - Part 1: Evaluation and<br>testing within a risk management process |
## Software Verification and Validation Testing
After evaluation of the specified use conditions, it could be demonstrated that the technical design including software flow and device usage of the Freddo is suitable to fulfill the specified intended use. In both formative and summative testing performed, no application problems were identified that could lead to any risk for the user, patient or third.
{9}------------------------------------------------
The verification of the software requirements was performed according IEC 62304. All the tests were performed successfully and met their acceptance criteria.
#### Biocompatibility Testing
The device has been assessed for the requirement of biocompatibility testing per ISO 10993-1. Since the device is not intended to contact the patient and the user contacts the device only through gloved hands, there are no additional biocompatibility requirements for the device.
#### Electrical safety and electromagnetic compatibility (EMC)
The device has undergone electrical and mechanical safety performance testing and electromagnetic compatibility testing. The system complies 60601-1 Edition 3.2 and 60601-1-2 Edition 4.1.
#### VIII. CONCLUSION:
The proposed indications for use for the Freddo are the same as those cleared in K060395. The subject device described in this submission is essentially the same device cleared in K060395. The Freddo device has the same intended use as the predicate and do not imply new technological characteristics.
According to the Risk-Benefit analysis, the global residual risk has been deemed acceptable since it falls in the area between negligible risks and acceptable risks.
The Freddo is substantially equivalent to the predicate device.